公开(公告)号：US20200069808A1

公开(公告)日：2020-03-05

申请号：US16675134

申请日：2019-11-05

Applicant: AMGEN INC.

Inventor： Gary LUEHR ,  Shabbir T. ANIK ,  Ge PENG ,  Irina DOTSENKO ,  Pasit PHIASIVONGSA ,  Dante ROMANINI

IPC: A61K47/60 ,  A61K9/00 ,  A61K38/07 ,  C08G65/333 ,  C07D405/12

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

公开(公告)号：US20210346513A1

公开(公告)日：2021-11-11

申请号：US16636325

申请日：2018-08-03

Applicant: AMGEN INC.

Inventor： Michal ACHMATOWICZ ,  Dante ROMANINI ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Oliver R. THIEL

IPC: A61K47/68 ,  C07K16/28 ,  C07K14/605

Abstract: The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality.

公开(公告)号：US20200376131A1

公开(公告)日：2020-12-03

申请号：US16857111

申请日：2020-04-23

Applicant: AMGEN INC.

Inventor： Gary LUEHR ,  Shabbir T. ANIK ,  Ge PENG ,  Irina DOTSENKO ,  Pasit PHIASIVONGSA ,  Dante ROMANINI

IPC: A61K47/60 ,  C07D405/12 ,  A61K9/00 ,  A61K38/07 ,  C08G65/333

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

公开(公告)号：US20220089756A1

公开(公告)日：2022-03-24

申请号：US17053728

申请日：2019-05-08

Applicant: Amgen Inc.

Inventor： John K. KAWOOYA ,  Alex W. JACOBITZ ,  Christopher MOHR ,  Stephen SMITH ,  Kevin GRAHAM ,  Ray Lieh Yoon LOW ,  Oliver THIEL ,  Dante ROMANINI ,  Victoria WAGNER ,  Neeraj J. AGRAWAL

IPC: C07K16/28 ,  C07K16/46

Abstract: The present invention is directed to a CH3-containing molecule comprising (a) a first polypeptide comprising a CH3 domain and a negatively charged domain comprising consecutive negatively charged amino acid residues; and (b) a second polypeptide comprising a CH3 domain and a positively charged domain comprising consecutive positively charged amino acid residues. Also provided are methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.

公开(公告)号：US20170340746A1

公开(公告)日：2017-11-30

申请号：US15602823

申请日：2017-05-23

Applicant: AMGEN INC.

Inventor： Gary LUEHR ,  Shabbir T. ANIK ,  Ge PENG ,  Irina DOTSENKO ,  Pasit PHIASIVONGSA ,  Dante ROMANINI

IPC: A61K47/60 ,  C08G65/333 ,  A61K9/00 ,  A61K38/07

Abstract: The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.